5/9/2025

NEW YORK and NEW ORLEANS, May 9, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June...

Source: Finnhub

5/9/2025

TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.

Source: Yahoo

5/9/2025

Despite a revenue dip and goodwill impairment, Viatris Inc (VTRS) focuses on strategic growth, shareholder returns, and promising new product developments.

Source: Yahoo

5/9/2025

Q1 2025 Viatris Inc Earnings Call

Source: Yahoo

5/9/2025

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. of a class action securities lawsuit. ...

Source: Finnhub

5/8/2025

Viatris Inc. stock rises Thursday, outperforms market

Source: MarketWatch

5/8/2025

VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.

Source: Yahoo

5/8/2025

Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.

Source: Yahoo

5/8/2025

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Source: Yahoo

5/8/2025

Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read why VTRS stock is a sell.

Source: SeekingAlpha

5/8/2025

Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/8/2025

CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $3.04 billion in its first quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of $2.55.

Source: Yahoo

5/8/2025

Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1].

Source: Yahoo

5/8/2025

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 inves

Source: Yahoo

5/8/2025

Viatris Inc. (NASDAQ:VTRS) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott Smith -...

Source: SeekingAlpha

5/8/2025

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of

Source: Yahoo

5/8/2025

The following slide deck was published by Viatris Inc.

Source: SeekingAlpha

5/8/2025

Drugmaker Viatris beat WallStreet estimates for first-quarter profit and revenue onThursday, helped by sales of its branded drugs in China. The company's shares, which rose over 4% in...

Source: Finnhub

5/8/2025

Q1 2025 Financial Results Total Revenues $3.3B A...

Source: Finnhub

5/8/2025

‌GAAP / Non-GAAP Reconciliations This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third...

Source: Finnhub